NuVasive, Inc. (NASDAQ:NUVA) received a $60.00 target price from investment analysts at Robert W. Baird in a note issued to investors on Thursday. The brokerage currently has a “hold” rating on the medical device company’s stock. Robert W. Baird’s target price would suggest a potential upside of 18.62% from the company’s previous close.

Several other equities analysts have also recently weighed in on the company. Needham & Company LLC cut NuVasive from a “hold” rating to an “underperform” rating in a report on Monday, August 28th. BTIG Research initiated coverage on NuVasive in a report on Thursday, September 7th. They issued a “buy” rating and a $82.00 price objective for the company. Cowen and Company reaffirmed an “outperform” rating and issued a $83.00 price objective on shares of NuVasive in a report on Monday, September 18th. BidaskClub raised NuVasive from a “hold” rating to a “buy” rating in a report on Wednesday, July 19th. Finally, Zacks Investment Research cut NuVasive from a “buy” rating to a “hold” rating in a report on Monday, July 31st. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $76.62.

NuVasive (NASDAQ NUVA) traded down 0.36% on Thursday, reaching $50.40. The company’s stock had a trading volume of 1,305,595 shares. NuVasive has a 12 month low of $49.25 and a 12 month high of $81.68. The company has a 50-day moving average price of $57.81 and a 200 day moving average price of $69.71. The company has a market cap of $2.56 billion, a P/E ratio of 79.37 and a beta of 1.03.

NuVasive (NASDAQ:NUVA) last announced its quarterly earnings data on Thursday, July 27th. The medical device company reported $0.46 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.44 by $0.02. The firm had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $261.95 million. NuVasive had a return on equity of 13.04% and a net margin of 3.50%. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.40 EPS. On average, equities research analysts anticipate that NuVasive will post $1.99 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This news story was posted by American Banking News and is owned by of American Banking News. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright & trademark laws. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/12/robert-w-baird-reaffirms-hold-rating-for-nuvasive-inc-nuva.html.

In other NuVasive news, Director Lesley H. Howe sold 3,970 shares of the company’s stock in a transaction dated Friday, August 18th. The stock was sold at an average price of $64.64, for a total value of $256,620.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Gregory T. Lucier bought 2,000 shares of the stock in a transaction on Tuesday, August 29th. The stock was purchased at an average cost of $61.52 per share, with a total value of $123,040.00. The disclosure for this purchase can be found here. In the last ninety days, insiders acquired 14,850 shares of company stock valued at $955,598. Insiders own 1.20% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. increased its holdings in NuVasive by 1.3% in the 2nd quarter. Vanguard Group Inc. now owns 4,164,226 shares of the medical device company’s stock worth $320,312,000 after purchasing an additional 53,769 shares in the last quarter. State Street Corp increased its holdings in NuVasive by 4.2% in the 2nd quarter. State Street Corp now owns 1,710,341 shares of the medical device company’s stock worth $131,562,000 after purchasing an additional 68,344 shares in the last quarter. Voya Investment Management LLC increased its holdings in NuVasive by 43.7% in the 2nd quarter. Voya Investment Management LLC now owns 1,699,964 shares of the medical device company’s stock worth $130,761,000 after purchasing an additional 517,115 shares in the last quarter. Koch Industries Inc. increased its holdings in NuVasive by 26,406.7% in the 2nd quarter. Koch Industries Inc. now owns 982,337 shares of the medical device company’s stock worth $970,000 after purchasing an additional 978,631 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in NuVasive by 2.6% in the 2nd quarter. Northern Trust Corp now owns 837,154 shares of the medical device company’s stock worth $64,393,000 after purchasing an additional 21,340 shares in the last quarter.

NuVasive Company Profile

Nuvasive, Inc is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process.

Analyst Recommendations for NuVasive (NASDAQ:NUVA)

Receive News & Ratings for NuVasive Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive Inc. and related companies with MarketBeat.com's FREE daily email newsletter.